Live News EQUITY FLASH L impact Oct 27, 2026, 01:18 PM UTC NanoViricides expects Ebola study of NV-387 to enter Phase IIb NanoViricides expects its Ebola study of NV-387 to transition to Phase IIb. NNVC SquawkNews Desk